Floridienne (FLOB) H2 2025 earnings summary

Executive summary

• Turnover grew to EUR 725.9 million in 2025, driven by Life Sciences, despite adverse currency effects and hyperinflation in Turkey impacting profitability.

• Life Sciences Division saw strong growth, especially from BIOTROP, but profitability declined due to currency headwinds and amortisation of recent acquisitions.

• Food Division achieved stable performance with increased turnover, while Chemicals Division remained resilient despite lower purified metals prices and Turkish hyperinflation.

Financial highlights

• Consolidated turnover rose to EUR 725.9 million from EUR 697.4 million year-over-year.

• EBITDA decreased to EUR 110.0 million from EUR 116.8 million year-over-year.

• Net result after tax dropped to EUR 15.1 million from EUR 30.9 million year-over-year.

• Net result, Group share, was EUR 7.9 million, down from EUR 15.7 million.

• Net financial debt increased to EUR 266.4 million from EUR 209.5 million.

Outlook and guidance

• Confident outlook for 2026, expecting improved results, supported by investments in all divisions and regulatory tailwinds for biocontrol solutions in Europe.

• Life Sciences Division expected to benefit from international expansion and regulatory changes favoring biological solutions.

• Food Division investments in production capacity to support growth and profitability.

• Chemicals Division to increase volumes processed in 2026 with new battery recycling capacities.